Ketamine for PTSD: What the Research and Guidelines Say
When PTSD symptoms persist despite treatment, you may wonder whether ketamine therapy for PTSD could help. Research on ketamine for PTSD is mixed: a small controlled trial reported benefit, while a larger trial did not find a significant advantage on its principal PTSD outcomes. Ketamine is not FDA-approved for PTSD, and the 2023 VA/DoD guideline suggests against using it for this condition.
That does not mean your remaining symptoms should be dismissed. It means the next step should be a careful review of your diagnosis, previous care, and evidence-based options—not an assumption that ketamine is the established answer when therapy has been difficult.
Ketamine treatment for PTSD: how guidelines weigh the evidence
The VA's clinician guide to PTSD medications summarizes the 2023 VA/DoD recommendation against ketamine for PTSD, reflecting uncertain benefit and the medication's risks. It also distinguishes treating PTSD from treating co-occurring medication-resistant depression.
A guideline considers a body of evidence rather than one striking result. That is why a positive study does not necessarily produce a recommendation for routine care. A cautious recommendation does not prove that no individual could benefit, but it should be part of an honest treatment discussion.
Ask a clinician to explain both the evidence supporting a proposal and the evidence that limits it. A service should not cite ketamine's depression research as though it automatically establishes effectiveness for nightmares, avoidance, intrusive memories, or other PTSD symptoms.
A small trial found promising short-term results
A 2021 randomized trial in chronic PTSD assigned 30 participants to repeated intravenous ketamine or midazolam, an active comparison treatment. Participants received six infusions over two weeks. At the two-week assessment, the ketamine group had greater improvement on the clinician-rated PTSD measure, and the reported response rates were 67% versus 20%.
The sample was small, and a response was not equivalent to permanent recovery. Among ketamine responders, the median time to loss of response was 27.5 days after the course. That number describes selected responders in this study; it is not a recommended interval for repeating treatment.
The findings justified further research. They did not establish a universal success rate, prove a lasting psychotherapy benefit, or show that all ketamine formulations would produce the same result.
A larger trial did not confirm a clear PTSD benefit
A 2022 multicenter trial in veterans and service members enrolled 158 people with PTSD after previous antidepressant treatment had not been adequate. It compared two intravenous ketamine dose groups with placebo across eight infusions over four weeks.
The study did not find significant group-by-time differences on the PTSD symptom measures. The standard-dose group did show a greater improvement in depression scores than placebo in a secondary analysis. This distinction matters: a depression improvement is not automatically evidence of improvement in the core PTSD outcome.
The trials differed in participants, design, and treatment conditions. It would be misleading to report only the smaller positive study or to combine unlike results into one advertised response rate. The overall picture remains more uncertain than a simple claim that ketamine treats resistant trauma.
Watch the video: PTSD Treatment Works (U.S. Department of Veterans Affairs)
Review what kind of therapy has actually been tried
The VA overview of PTSD psychotherapy identifies prolonged exposure, cognitive processing therapy, and EMDR as strongly recommended trauma-focused approaches. General supportive counseling is not necessarily the same intervention as a structured PTSD treatment.
That distinction should not be used to blame you or dismiss the effort you have already made. Ask what treatment was delivered, whether the approach matched your symptoms, and what interrupted or limited the course. Access problems, poor fit, adverse experiences, and persistent symptoms may call for different next steps.
You can ask about another evidence-based approach, medication options when appropriate, specialist consultation, or support addressing practical barriers. No one should assume that a difficult experience with one therapist proves that all established care has been exhausted.
Separate the treatment goals when depression and PTSD overlap
A person can have PTSD and depression at the same time. Less hopelessness or improved energy would matter, but it would not automatically mean that avoidance, intrusive memories, or trauma-related distress had improved to the same degree.
Ask which condition is the reason for a proposed medication and how each outcome will be followed. A hypothetical review might identify better concentration alongside persistent nightmares. That mixed report is clinically useful; it should not be relabeled as complete PTSD recovery.
The same caution applies to claims that ketamine unlocks memories or enables deeper trauma processing. The trials described here do not establish that mechanism as a guaranteed therapeutic pathway. A compelling explanation about the brain or an intense medication experience does not replace measurement of meaningful symptom change.
Off-label use still requires a clear safety discussion
The FDA's ketamine product information distinguishes approved anesthetic ketamine from psychiatric claims and from Spravato, the branded esketamine product. An anesthetic approval is not a PTSD approval, and a compounded nasal product is not Spravato simply because both use the nose.
Before considering a proposed service, ask about the exact product, route, medical assessment, monitoring, emergency response, and follow-up. Explain other medications and substance use honestly. Do not change prescribed treatment independently or attempt to reproduce a clinical protocol outside care.
Clarify whether psychotherapy is included and what evidence supports the combined service. Preparation or “integration” sessions should not be used to imply that the medication's uncertainties and risks disappear. A clinician should explain alternatives and what would lead to reconsidering the plan.
Questions that make the next appointment more useful
Start with your current priorities: nightmares, avoidance, feeling constantly on guard, mood, sleep, relationships, or another difficulty. Ask which treatment options have the strongest evidence for those problems in the context of your history.
Ask how your previous care will be reviewed and whether there are established options you have not yet been able to access. Bring treatment names, approximate dates, what helped, what did not, and reasons for stopping. You do not need perfect records to begin the discussion.
If ketamine is proposed, ask directly: “How do you interpret the mixed trials and the guideline recommendation for my situation? Are we treating PTSD, depression, or both?” Request a clear plan for monitoring benefit, adverse effects, and continuation. Uncertainty should be explained before a financial or treatment commitment, not discovered afterward.
Discussing persistent symptoms with Sophroneo
Sophroneo Behavioral Health & TMS provides PTSD-related care and therapy and counseling from locations in Powder Springs and Marietta in the Atlanta area. Contact Sophroneo to discuss assessment and confirm which treatment approaches are available. This article does not state that the practice offers ketamine specifically for PTSD or every psychotherapy named above.
Frequently asked questions
Are ketamine or Spravato FDA-approved for PTSD?
No. Ketamine's approval as an anesthetic does not include PTSD. Spravato's specific depression indications are also not PTSD approval. A clinician should clearly identify the condition being treated and whether a proposed use is off-label.
Does the larger negative trial mean the smaller positive trial was meaningless?
No. Both contribute evidence, but neither should be interpreted alone. Differences in samples and methods matter. Together they support a more cautious conclusion than an advertisement claiming a reliable PTSD success rate.
What should I do when previous therapy has not helped enough?
Ask for a structured review of the diagnosis, the therapy delivered, barriers to completing treatment, and available alternatives. Persistent symptoms deserve further care, but they do not automatically make ketamine the next evidence-based choice.
In the United States, call or text 988 for emotional crisis support or suicidal thoughts. For immediate danger or a life-threatening emergency, call 911. Routine treatment scheduling should not delay urgent help.
This article reviews selected studies and guideline recommendations for education. It is not an individual treatment recommendation or a complete systematic evidence review.
Comments